FTC Hinges Lupin, Hikma Acquisitions On Divestitures
This article was originally published in Scrip
Executive Summary
Before Lupin Ltd. can complete its acquisition of Gavis Pharmaceuticals LLC for $765.6m and its related company Novel Laboratories Inc. for $83.6m, the firms must sell their rights to generic versions of doxycycline monohydrate and mesalamine G&W Laboratories, the Federal Trade Commission (FTC) said on Feb. 19, in revealing a new agreement with the firms containing consent orders for divesting the products.